Scope of the Study
Hormonal contraceptives such as the pill, the patch, and the vaginal ring contain a small amount of man-made estrogen and progestin hormones. These hormones inhibit the body's natural cyclical hormones to prevent pregnancy. It stops the body from ovulating. It can also change the lining of the womb, which makes it unlikely the fertilized egg will be implanted. It is primarily used for the prevention of pregnancy. It can be also prescribed for the treatment of polycystic ovary syndrome, menstrual disorders such as dysmenorrhea and menorrhagia, and hirsutism.
The market study is being classified by Type (Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings and Transdermal Patches) and major geographies with country level break-up.
Ansell (Australia), Bayer AG (Germany), Church & Dwight Co (United States), Johnson & Johnson (United States), Merck & Co., Inc. (United States), Mylan N.V. (United States), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), The Female Health Company (United States) and Organon International (Netherlands) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Afaxys, Inc. (United States).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Hormonal Contraceptive market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Hormonal Contraceptive market by Type, Application and Region.
On the basis of geography, the market of Hormonal Contraceptive has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Use of Hormonal Contraceptives
- Ease of Availability of the Contraceptives
- Growing Number of Online Pharmacies
- Increasing Awareness among People about Emergency Contraception
- Increasing Adoption of Long-acting Contraceptive Methods
- Side Effects such as Headaches and Breakthrough Bleeding between Periods
- Availability of the Alternative Products
- Growing Demand from Developing Countries
- Growth in the Health Care Industry
- Increasing Promotional Activities of the Companies
- Stringent Government Rules and Regulations
Market Leaders and their expansionary development strategies
In January 2020, Theramex has announced that it has entered into a definitive agreement to acquire further rights to Zoely, a patented oral contraceptive, from MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Theramex currently markets Zoely in eleven European countries, and this transaction will bring the total number of markets up to more than 50 on a global basis. MSD retains rights in the United States and Canada.
Key Target AudienceHormonal Contraceptives Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase